Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.64 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | XDH | P47989 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6083470 | 1.00 | SLC6A4 (0.64) | SLC6A4IMPDH2SLC6A2SLC6A3XDH | |
| SCHEMBL6084082 | 0.78 | SLC6A4 (1.00) | SLC6A4IMPDH2SLC6A2SLC6A3 | |
| SCHEMBL6084079 | 0.78 | SLC6A4 (1.00) | SLC6A4IMPDH2SLC6A2SLC6A3 | |
| SCHEMBL6084265 | 0.76 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6084271 | 0.76 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6084473 | 0.76 | SLC6A4 (0.60) | SLC6A4IMPDH2SLC6A2XDH | |
| SCHEMBL6084459 | 0.74 | SLC6A4 (0.56) | SLC6A4IMPDH2XDH | |
| SCHEMBL6084452 | 0.74 | SLC6A4 (0.56) | SLC6A4IMPDH2XDH | |
| SCHEMBL6084783 | 0.73 | SLC6A4 (0.62) | SLC6A4IMPDH2SLC6A2SLC6A3 | |
| SCHEMBL6084773 | 0.73 | SLC6A4 (0.62) | SLC6A4IMPDH2SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105516-B2 | Compounds for the treatment of premature ejaculation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-12 | — | — | US | disclosed |
| US-20040063768-A1 | Compounds for the treatment of premature ejaculation | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063768-A1 | Compounds for the treatment of premature ejaculation | HTR5A, SLC18A2, CYP17A1 | SLC6A4 12/4885IMPDH2 1866/4885SLC6A2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.